Augmedix, Inc.

Augmedix, Inc.

AUGX
Augmedix, Inc.US flagNASDAQ Capital Market
2.35
USD
+0.00
- -
115.91MMarket Cap
Augmedix, Inc.
AUGX
(NASDAQ Capital Market)

Recent

price

2.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
TTM
FRC
0.53
0.61
0.59
0.83
1.02
1.03
Revenue per Share
-0.69
-0.58
-0.47
-0.65
-0.44
-0.47
Basic EPS, GAAP
-0.58
-0.56
-0.51
-0.49
-0.42
-0.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.54
-3.12
-2.71
-3.36
-3.3
-3.18
Book Value per Share
-2.42
0.12
0.64
0.04
0.53
0.21
Tangible Book Value per Share
27
27
37
37
44
50
Basic Weighted Avg Shares
14
16
22
31
45
52
Sales/Revenue/Turnover
-118.68
-83.07
-79.18
-72.32
-41.87
-46.29
Operating Margin (%)
1
1
1
1
1
1
Depreciation Expense
-18
-16
-17
-24
-19
-24
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-131.12
-94.67
-78.79
-79.04
-42.74
-46.23
Profit Margin (%)
1
10
37
10
33
16
Working Capital
10
8
13
12
19
19
LT Debt
-65
3
24
1
23
10
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
6
9
6
LT Borrowings
15
13
16
LT Finance Leases
4
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
257
196
44

Working Capital

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
57
50
40
Cash, Cash Equivalents & STI
46
37
28
Accounts Receivable, Net
9
10
9
Inventories
- -
- -
- -
Total Current Liabilities
24
25
24
Payables & Accruals
3
4
5
ST Debt
6
9
6
Deferred Revenue
10
10
10

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
1,490.79%
Free Cash Flow
- -
- -
2.01%
Net Income, GAAP
- -
- -
-21.59%
Sales/Revenue/Turnover
- -
- -
45.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
7
7
8
9
31
2023
10
11
12
13
45
2024
13
14
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.16
-0.2
-0.15
-0.15
-0.65
2023
-0.14
-0.12
-0.1
-0.09
-0.44
2024
-0.12
-0.16
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Business
Augmedix, Inc. (Nasdaq: AUGX) develops and provides ambient AI-powered medical documentation and data solutions that enable clinicians to focus on patient interactions by automating note generation and administrative tasks for healthcare systems, hospitals, physician practices, and telemedicine providers primarily in the United States. The company offers a suite of products including Augmedix Live, which delivers synchronous real-time medical note documentation and point-of-care support through ambient AI and trained medical documentation specialists; Augmedix Go, an autonomous fully automated AI mobile application for generating notes from recorded visits, including a specialized version for emergency departments developed in partnership with HCA Healthcare; Augmedix Assist, providing asynchronous documentation with AI-drafted notes plus human support for editing, coding, orders, and referrals; and Augmedix Prep, which supplies pre-visit chart preparation with patient demographics, medical history, and medication updates; all integrated with major electronic health records such as Epic, Cerner, Meditech, and athenahealth, supporting 32 languages, real-time care gap reminders via CareCues, and HITRUST-certified HIPAA-compliant security. Founded in 2013 and headquartered at 111 Sutter Street, Suite 1300, in San Francisco, California, Augmedix operates its proprietary Notebuilder Platform leveraging automatic speech recognition, natural language processing, and large language models to transform clinician-patient conversations into structured notes and actionable data insights across specialties like oncology and emergency medicine. In July 2024, Augmedix entered a definitive agreement to be acquired by Commure, Inc. in an all-cash transaction valued at approximately $139 million, or $2.35 per share, positioning it as a wholly-owned subsidiary to accelerate AI innovations, expand integrations, and scale services across more health systems; the deal, expected to close in late 2024 or early 2025 subject to stockholder approval and customary conditions, follows prior name change from Malo Holdings Corporation in October 2020 and builds on collaborations such as with HCA Healthcare for emergency department solutions.

Company News

APIChat
  • Commure Completes Merger with Augmedix

  • 7 AI Penny Stocks to Watch in October

  • STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX

  • Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

  • Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

  • STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX

  • Why Is Augmedix (AUGX) Stock Up 150% Today?

  • Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

  • Augmedix to Join Forces with Commure

  • Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments

  • Augmedix Reiterates Second Quarter and Full Year 2024 Outlook

  • Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

  • Why Is Augmedix (AUGX) Stock Down 41% Today?

  • Augmedix, Inc. (AUGX) Q1 2024 Earnings Call Transcript

  • Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

  • Augmedix to Participate in Upcoming Investor Conferences in May and June 2024

  • Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

  • 3 Penny Stocks That Could Make a Big Comeback by the End of Q2

  • Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care

  • Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide